Hypersensitivity pneumonitis possibly caused by riluzole therapy in ALS

Neurology

Volumn 61, Issue 8, 2003, Pages 1150-1151

  Cassiman, David ^a   Thomeer, Michiel ^a   Verbeken, Erik ^a   Robberecht, Wim ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBON MONOXIDE; LANSOPRAZOLE; METHYLPREDNISOLONE; OMEPRAZOLE; RILUZOLE;

AGED; ALLERGIC PNEUMONITIS; AMYOTROPHIC LATERAL SCLEROSIS; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGITIS; HUMAN; LABORATORY TEST; LUNG AUSCULTATION; LUNG BIOPSY; LUNG FIBROSIS; LUNG FUNCTION TEST; MALE; PRIORITY JOURNAL; SYMPTOM; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

EID: 0344896704     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000082385.33604.1D     Document Type: Article

References (4)

1. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2002;2:CD00144.7.
2. Gurney ME, Fleck TJ, Himes CS, Hall ED. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 1998;50:62-66.
3. Lacomblez L, Bensimon G, Leigh PN, et al. Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3:23-29.
4. Pontgratz D, Neundorfer B, Fischer W. German open label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS). J Neurol Sci 2000;180:82-85.